NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
87 trialsNCT07100730 2026-03-12
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05382338 2026-02-24
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Children's Oncology Group
Phase 3 Recruiting
NCT05095376 2026-02-17
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05331521 2026-02-03
ImproveCodel
University Hospital Heidelberg
Phase 3 Recruiting
NCT00887146 2026-01-22
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT04402073 2025-10-23
PersoMed-I
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT07145112 2025-10-09
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
Phase 1 Recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT07120984 2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT04762069 2025-05-04
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting
NCT00085735 2025-01-14
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Children's Oncology Group
Phase 3 Completed
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT06419946 2024-11-19
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Not yet recruiting
NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT00003375 2024-07-09
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
Radiation Therapy Oncology Group
Phase 2/3 Completed
NCT04573192 2024-04-08
GLIOSTAR
Philogen S.p.A.
Phase 1/2 Recruiting
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05898451 2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2 Completed
NCT05410301 2023-04-21
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
University of Iowa
Phase NA Withdrawn
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT05017610 2022-12-02
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Emory University
Phase EARLY_PHASE1 Withdrawn
NCT01775475 2022-10-10
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT02926222 2022-09-09
REGOMA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT05518383 2022-08-26
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4 Recruiting
NCT02843230 2022-04-08
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Massachusetts General Hospital
Completed
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT02212574 2021-11-05
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated
NCT02076152 2021-07-30
FMISO PET Study of Glioblastoma
Massachusetts General Hospital
Phase NA Completed
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT03025893 2021-04-19
STELLAR
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT02678975 2021-03-18
Disulfiram in Recurrent Glioblastoma
Sahlgrenska University Hospital
Phase 2/3 Completed
NCT01290939 2021-02-15
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT01934361 2020-12-09
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Novartis
Phase 1 Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT00058370 2020-05-11
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01614132 2020-03-31
NOA-07
University of Regensburg
Phase 1/2 Completed
NCT01067469 2020-03-17
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT00004259 2019-09-12
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01562197 2019-01-24
AxiGII
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed